Ali Nahvi
Chief Technology Officer Nava Therapeutics
Ali Nahvi is the Chief Technology Officer at Nava Therapeutics where he is responsible for steering the company’s technology and innovation initiatives including chemistry, LNP discovery, targeted delivery, process development and manufacturing.
Prior to joining Nava, Ali was the Head of Platform at Flagship Pioneering’s Mirai Bio, where he helped to start the company from inception, implement the company’s scientific strategy and led it through to its next stage of growth. Previously, Ali served as Head of New Therapeutic Modalities at Spark Therapeutics and was responsible for driving research-related activities to expand the applicability of AAV and non-viral gene therapy platforms.
Ali holds a Ph.D. from Yale University and was a Life Sciences Research Foundation postdoctoral fellow at Johns Hopkins School of Medicine characterizing the mechanisms of RNA mediated gene regulation.
Seminars
- Targeted lipid nanoparticle platform facilitates generation of transient CAR-T cells to allow rapid B cell depletion without lymphodepletion
- In non-human primates, delivery of an anti-CD20 CAR mRNA induced profound B cell depletion in blood and lymphoid tissues including spleen, bone marrow and lymph nodes
- Demonstrating excellent safety and tolerability, the off-the-shelf candidate allows B cells recovery to occur with predominately naïve phenotypes, supporting immune reset and translational potential for autoimmune diseases
